BSX · NYSE · Surgical & Medical Instruments & Apparatus

Boston Scientific Corp

A research memo on Boston Scientific after a 60% share-price fall: what it sells and where its catheters sit in one AF patient, the EP and Watchman slowdown, the August 2026 cyber outage, the Penumbra deal arithmetic, 2028 scenarios, a 30 Oct 2026 valuation, and a leadership, guidance and insider review.

What we have on this company
Information	Status	As of
Detailed research report	Yes	2026-10-31
Rule-based screens	On 1 shortlist: Most insider buying	2026-10-31
Valuation	Model 44.75 (+7% vs price); Below fair value · +20% to USD 50.43	2026-10-31, 2026-10-30
Chart-pattern read	Down -9% to target, Ascending broadening formation (possible)	2026-10-30
Paper portfolio	Held since 2026-10-15	2026-10-30

Research

Detailed report · reviewed 2026-10-31 · financial baseline Q3 2026

A quality franchise priced for a two-engine stall

Quality at a value multiple. At USD 41.98 (30 Oct 2026) the shares trade on about 13x 2026 adjusted EPS with about USD 3.6B of free cash flow, after three guidance cuts: EP (-5%) and Watchman (-6%) both declined in Q3 2026 and a cyber outage cost about 300 bps of growth, while the rest of the portfolio grows. The CEO and three directors bought shares in July and August. Scenario values today USD 29 bust, 46 base, 72 boom; TipRanks consensus USD 49.85. Penumbra closes early 2027; the Q4 report with 2027 guidance in early February 2027 is the next hard test.

Researched 31 Oct 2026 · IBKR ratings pending

Read the full report →

Scores

Deterministic rule outputs, snapshot 2026-10-31 · price 41.98 on 2026-10-30. Not recommendations.

On the current shortlists: Most insider buying (#2).

Method	Score	Inputs as of	Flags
Graham Defensive	26	2025-12-31	stale input
Magic Formula	88	2026-03-31	stale input
Momentum	12	2026-10-30
Insider	72	2026-10-30
Buffett Quality	67	2026-06-30	stale input
Lynch GARP	39	2026-06-30	stale input
Graham Enterprising	32	2026-06-30	stale input
Piotroski F-Score	89

Every input with its filing: full score sheet · research packet (JSON) · Markdown · SEC filings.

Valuation

Model estimate from SEC filings · calculated 2026-10-31 from the 2026-10-30 close · filings through 2026-08-03

44.75 +7% vs price

Range 27.40 to 67.90, 3 of 3 methods agree. A labelled model estimate, not a price target. Method.

Research fair-value comparison · latest source 2026-10-30

Below fair value · +20% to USD 50.43

Average of the dated sources shown in the report, with the price chart. Open the fair-value section.

Charts

Chart-pattern read from a notebook citing Bulkowski's Encyclopedia of Chart Patterns · forecast data to 2026-10-30 · 2 runs kept

Down -9% · Ascending broadening formation, possible

Book base rate 80% that such a breakout keeps going, once confirmed; 32% reached the full target. Historical frequencies, not a probability for this stock.

Open the chart → Forecast journal

Portfolio activity Paper

Simulated $50k paper account, not an investable fund · data as of the 2026-10-30 close

Held: 116.9 shares at an average cost of 44.22, 8.5% of the account, opened 2026-10-15; unrealized -5.07%.

Date	Action	Shares	Price
2026-10-15	BUY	116.9	44.22

See the position in the paper portfolio · all activity